A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Has received pneumococcal vaccine \>= 1 year before enrollment (PCV13, PCV15, PCV20, PPSV23, PCV13+PPSV23, PPSV23+PCV13, or PCV15+PPSV23). Exclusion Criteria: * Has a history of invasive pneumococcal disease (IPD). * Has a known hypersensitivity to any component of V116, PCV15, PCV20, or PPSV23, including diphtheria toxoid. * Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease. * Has a coagulation disorder contraindicating intramuscular vaccination. * Has a known malignancy that is progressing or has required active treatment. * Has received PPSV23 followed by either PCV15 or PCV20. * Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day). * Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease. * Has received any non-live vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine. * Has received any live virus vaccine ≤30 days before receipt of stu…